Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.63 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022638 | 1.00 | TACR1 (0.63) | TACR1OPRL1GRM5CYP3A4SIGMAR1 | |
| SCHEMBL4017891 | 1.00 | TACR1 (0.63) | TACR1OPRL1GRM5CYP3A4SIGMAR1 | |
| SCHEMBL4015909 | 0.95 | TACR1 (0.62) | TACR1OPRL1CYP3A4SIGMAR1 | |
| SCHEMBL4017832 | 0.95 | TACR1 (0.62) | TACR1OPRL1CYP3A4SIGMAR1 | |
| SCHEMBL4015913 | 0.95 | TACR1 (0.62) | TACR1OPRL1CYP3A4SIGMAR1 | |
| SCHEMBL4014194 | 0.87 | TACR1 (0.64) | TACR1OPRL1CYP3A4SIGMAR1 | |
| SCHEMBL4026665 | 0.87 | TACR1 (0.64) | TACR1OPRL1CYP3A4SIGMAR1 | |
| SCHEMBL4021108 | 0.87 | TACR1 (0.64) | TACR1OPRL1CYP3A4SIGMAR1 | |
| SCHEMBL4016794 | 0.84 | TACR1 (0.54) | TACR1OPRL1CYP3A4SIGMAR1 | |
| SCHEMBL4023487 | 0.84 | TACR1 (0.54) | TACR1OPRL1CYP3A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472222-A1 | PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066589-A1 | PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |